Across five phase III trials of SC golimumab , @ patients received placebo and @ received golimumab @ mg ( n = @ ) and/or @ mg ( n = @ ) up to wk @ ( patients may be included in more than one group because non-responders were allowed early escape ) ; @ patients were treated for @ weeks .